Compare · GLP-1 agonist
Orforglipron vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | VK2735 | |
|---|---|---|
| Evidence | 9/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a…
VK2735
VK2735 is an experimental obesity drug from a company called Viking Therapeutics. It's part of the incretin family (a group of gut-hormone-based drugs that turn down appetite) — the same broad family as semaglutide and tirzepatide. It has drawn a lot of buzz for two reasons: its early results in…